CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy | Low-Level Laser Therapy

Policy governs coverage of low-level laser therapy (photobiomodulation) for Medicare Advantage and commercial products, specifying covered indication (prevention of oral mucositis in at-risk cancer patients) and that all other indications are not covered/medically necessary. It also lists applicable procedure codes and relevant ICD-10 diagnosis code ranges for coverage.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy | Low-Level Laser Therapy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateNov 1, 2022

Next Review Date

Key ActionWhen billing the listed procedure codes, file the claim with applicable ICD-10-CM diagnosis codes (eg, C00-D49 or K12.30-K12.39) supporting prophylactic use for oral mucositis in patients undergoing cancer treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes.

1Covered Indications (prophylactic oral mucositis)

12+Listed Not-Covered Indications

3Procedure Codes Listed

179+Reference Count (approx)

Policy governs coverage of low-level laser therapy (LLLT) (photobiomodulation) for Medicare Advantage and commercial products, specifying coverage for prevention (prophylactic) of oral mucositis in at-risk cancer patients and stating that all other indications are not covered/not medically necessary. Procedure codes and diagnosis code ranges applicable for coverage are listed. Coverage stance: mixed — prophylactic LLLT for oral mucositis is covered when criteria are met; other indications are not covered due to insufficient evidence.

Effective date: 2022-11-01; Last review: 2025-10-01.

Policy metadata and brief summary

Effective date2022-11-01

Last review2025-10-01

Next review

Policy statusCURRENT

SubjectLow-Level Laser Therapy (LLLT) coverage

Brief summary of coverage stanceCovered prophylactically for prevention of oral mucositis in patients undergoing cancer treatment; not covered/insufficient evidence for other indications

Medical-Necessity Criteria

Medicare Advantage / Commercial Coverage Criteria

Covered when ALL of the following are met:

ALL of the following

Patient is undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic stem cell transplantation
Low-level laser therapy is used for prevention of oral mucositis (prophylactic use)

Evidence summary: The brief indicates sufficient evidence that prophylactic LLLT results in a meaningful improvement in net health outcome for prevention of oral mucositis in at-risk cancer patients, and that evidence is insufficient to determine effects for multiple musculoskeletal, neurologic, lymphedema, and wound-healing indications (evidence labels: "Sufficient evidence" — prophylactic LLLT for oral mucositis; "Insufficient evidence" — other listed indications). Recent randomized trials and systematic reviews are cited in support of the mucositis finding (see PLoS One 2014, Support Care Cancer 2007, and other systematic reviews/meta-analyses noted in the brief).

Not Covered / Not Medically Necessary Indications

LLLT is not covered/considered not medically necessary for all other indications because evidence is insufficient, including but not limited to:

ANY of the following

Carpal tunnel syndrome
Neck pain
Subacromial impingement
Adhesive capsulitis
Temporomandibular joint pain
Low back pain
Osteoarthritic knee pain
Heel pain (ie, Achilles tendinopathy, plantar fasciitis)
Rheumatoid arthritis
Bell palsy
Fibromyalgia
Wound healing / chronic non-healing wounds
Lymphedema

Rationale: LLLT is not covered for the numerous other listed indications because the evidence is judged insufficient to determine effects on health outcomes for those conditions (musculoskeletal, neurologic, lymphedema, wound healing, etc.), so these uses are considered not medically necessary under this policy.

Coding

Covered procedure codes when filed with listed ICD-10-CM diagnosis codesmixedCovered

0552T	Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional
97037	Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non ablative) for post-operative pain reduction
S8948	Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes

Applicable ICD-10-CM diagnosis codes for coverageICD-10Covered

C00-D49	Neoplasms (range) - malignancy/neoplasm diagnoses
K12.30-K12.39	Stomatitis and related diagnoses (oral mucositis codes range)

Billing and provider actions: Procedure codes (eg, 0552T, 97037, S8948) must be filed with the applicable ICD-10-CM diagnosis codes (eg, C00–D49 or K12.30–K12.39) that support prophylactic use for oral mucositis in patients undergoing cancer treatment. Claims for covered LLLT depend on correct CPT/HCPCS and ICD-10 linkage to document the qualifying diagnosis.

Provider Actions & Billing Rules

Documentation Required

Link procedure to qualifying diagnosis

When billing the listed procedure codes, file the claim with applicable ICD-10-CM diagnosis codes that support prophylactic use for oral mucositis in patients undergoing cancer treatment (eg, malignancy/neoplasm or oral mucositis codes). Affected codes: 0552T, 97037, S8948, C00-D49, K12.30-K12.39.

Billing Rule

Use correct CPT/HCPCS & ICD-10 linkage

The listed LLLT procedure codes are covered only when filed with the ICD-10-CM diagnosis codes indicated; verify correct CPT/HCPCS and ICD-10 linkage when submitting claims. Affected codes: 0552T, 97037, S8948, C00-D49, K12.30-K12.39. Note: benefits may vary between groups and contracts.

Documentation Required

Member benefit determination

Member-specific benefits and eligibility are determined by the member's subscriber agreement, certificate, or employer agreement which supersede this policy. For member-specific benefit information, verify via the provider call center before delivering LLLT services.

Denial Risk

Potential member liability for non-covered services

If services are determined to be not medically necessary or are non-covered benefits, do not charge the member unless the member was informed and agreed in writing in advance to continue treatment at their own expense.

Documentation Required

Policy changes

BCBSRI reserves the right to review and revise this policy at any time, with or without notice; clinical practices and technology changes may prompt revisions.

Background & Definitions

Background: Low-level laser therapy (LLLT), also called photobiomodulation, uses red-beam or near-infrared lasers with wavelengths between 600–1000 nm and power between 5 and 500 mW to produce nonthermal photobiostimulative effects; the exact mechanism is uncertain but hypotheses include improved cellular repair and stimulation of immune, lymphatic, and vascular systems. When applied to the skin LLLT produces no sensation and does not burn. The evidence base supports prophylactic use of LLLT for prevention of cancer therapy–associated oral mucositis in at-risk patients, while evidence is insufficient for other indications listed in the policy.

Term	Definition
Low-level laser therapy (LLLT)
Use of red-beam or near-infrared lasers (wavelength 600–1000 nm) and power between 5 and 500 mW producing nonthermal photobiostimulative effects.
Oral mucositis
Inflammation of the oral mucosa manifesting as erythema or ulcerations typically 7–10 days after initiation of high-dose cancer therapy.

Evidence Summary

Summary of evidence: Sufficient evidence supports prophylactic LLLT for prevention of oral mucositis in patients at increased risk from cancer therapies. Insufficient evidence exists for multiple other indications including a range of musculoskeletal (eg, carpal tunnel syndrome, neck pain, knee osteoarthritis), neurologic (eg, Bell palsy), lymphedema, and chronic wound-healing conditions. The brief references multiple randomized trials and systematic reviews/meta-analyses (examples cited in the policy include PLoS One 2014, Support Care Cancer 2007, and later systematic reviews and meta-analyses) supporting the mucositis conclusion.

References & evidence strength (compact)

Reference count (approx)References: 179+ citations listed

Evidence strength for covered indicationSufficient evidence supports prophylactic LLLT for prevention of oral mucositis in at-risk cancer patients

Evidence strength for other indicationsInsufficient evidence for multiple musculoskeletal, neurologic, wound-healing, and lymphedema indications

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy | Low-Level Laser Therapy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateNov 1, 2022

Next Review Date

SourceLink

On This Page

OpenPayer

Medical Coverage Policy | Low-Level Laser Therapy

Coverage Summary

Medical-Necessity Criteria

Not Covered / Not Medically Necessary Indications

Coding

Provider Actions & Billing Rules

Background & Definitions

Evidence Summary

Revision History